CD19 and acute lymphoblastic leukemia: The 2 aforementioned institutions all infused CAR-T cells at a relatively broad dose range, while a fixed dose of either 1 × 106 or 3 × 106 CAR-T cells/kg was employed in a phase I dose escalation study (NCT01593696) performed at the NCI to investigate anti-CD19 28ζ CAR-T cells for children and young adults with R/R B-ALL (Lee et al., 2015a).